ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC).Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 29, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

First US Trial to Test Aerosolized Chemo in Advanced Cancers First US Trial to Test Aerosolized Chemo in Advanced Cancers
A team of US researchers is investigating whether pressurized intraperitoneal aerosolized chemotherapy (PIPAC) can benefit patients with advanced cancer and peritoneal carcinomatosis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases
Second-look surgery plus oxaliplatin HIPEC is no better than standard surveillance at prolonging disease-free survival for patients with colorectal peritoneal metastases, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

CRC With Peritoneal Metastases: CRS-HIPEC Refinements CRC With Peritoneal Metastases: CRS-HIPEC Refinements
Refinements to the treatment pathway may improve overall survival in patients with colorectal cancer who have peritoneal metastases, suggest four new studies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Olaparib/Bevacizumab Maintenance FDA Approves Olaparib/Bevacizumab Maintenance
The FDA has announced a new approved indication for olaparib in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Niraparib for Advanced Ovarian Cancer
The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Ovarian cancer: recognition and initial management [CG122], NICE (Published 27th April)
This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment. This guideline was previously called ovarian cancer: the recognition and initial management of ovarian cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 27, 2020 Category: Consumer Health News Source Type: news

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
FDA medical oncologists discuss the agency ’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Niraparib for Advanced Ovarian Cancer with HRD+ Status Approved by FDA
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - October 23, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Surgery for Intraperitoneal Metastases From Lung Cancer Surgery for Intraperitoneal Metastases From Lung Cancer
This case series demonstrates that cytoreductive surgery for diffused peritoneal metastases from lung cancer can yield improved prognosis and long-term survival.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news